Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to ...

Prostate cancer treatments carry different risks. Dr. Fernando Bianco argues for informed decisions that balance cancer ...

A crowd of South African men ran through the streets of Johannesburg in purple swim briefs to raise awareness about prostate ...

A radioactive treatment for advanced prostate cancer produced encouraging results in routine French medical practice, ...

A molecular test could help doctors decide which men with high-risk prostate cancer need additional hormone treatment, ...

Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with ...

Johnson & Johnson (NYSE:JNJ) today announced promising Phase 1 results for JNJ-6143 (formerly HLD-0915), an investigational once-daily oral Regulated Induced Proximity Targeting Chimera (RIPTAC) small ...

Prostate cancer is the most common cancer in men—in 2013, it affected more than 1 million men across the world. The cancer ...

A French early-access program of 3,709 patients with metastatic castration-resistant prostate cancer found that ...

Improvements in the PSA screening process make it worth another look.

Proteins linked to the immune system, cell adhesion, blood vessel formation and known prostate cancer genes were associated with the future risk of developing prostate cancer, including aggressive ...

Johnson & Johnson (JNJ) stock fell 1% to $263.81 as its prostate cancer pill JNJ-6143 posted a 75% tumor response in Phase 1 ...